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Summary 
The contribution of major histocompatibility complex (MHC) dass I-peptide affinity to im- 
munodominance of particular peptide antigens (Ags) in the dass I-restricted cytotoxic T lymphocyte 
(CTL) response is not clearly established.  Therefore,  we have compared the H-2Kb-restrict  - 
ed binding and presentation of the immunodominant ovalbumin  (OVA)257-~4 (SIINFEKL) 
determinant to that of a subdominant OVA determinant OVAss-62 (KWRFDKL). Immuno- 
dominance of OVA2sy-264 was not attributable to the specific T  cell repertoire  but correlated 
instead with more efficient Ag presentation.  This enhanced Ag presentation could be accounted 
for by the higher affinity of Kb/OVA2s7_2ea compared with Kb/OVAss-62 despite the presence 
of a conserved Kb-binding motif in both peptides.  Kinetic binding studies using purified sol- 
uble H-2K  b molecules (Kbs) and biosensor techniques indicated that the Kon for association of 
OVA2s7-~c~s and Kbs at  25~  was  ",,10-fold faster (5.9  x  103 M -1  s -t  versus 6.5  x  102 
M -1 s-t), and the Ko~ approximately twofold slower (9.1  x  10 -6 s -1 versus 1.6  x  10 -5 s-l), 
than the rate constants for interaction of OVAss-62-c6 and Kbs. The association of these peptides 
with K b was significantly influenced by multiple residues at presumed nonanchor sites within 
the peptide sequence. The contribution of each peptide residue to Kb-binding was dependent 
upon the sequence context and the summed contributions were not additive. Thus the affinity 
of MHC class I-peptide binding is a critical factor controlling presentation  of peptide Ag and 
immunodominance in the class I-restricted CTL response. 
M 
HC class I molecules act as receptors for endogenous 
Ags by assembling with peptide fragments created in 
the cytoplasm  and then delivered to a pre-Golgi compart- 
ment. Peptides associated with class I molecules are gener- 
ally 8-10 amino adds in length (1-3) and are imported into 
the vacuolar system via multidrug-resistant pumplike mole- 
cules (transporter associated with Ag processing [TAP] mol- 
ecules) encoded within the MHC (4-7). The factors likely 
to control which peptide Ags are presented to class 1-restricted 
T cells include the processing machinery which creates cyto- 
solic peptides (8), selectivity in the transport of peptides by 
TAP molecules (9, 10), and the affinity of peptide interaction 
with class I molecules. In class II-restricted immunity, re- 
sponsiveness to particular peptides correlates strongly with 
the capacity of these peptides  to bind the relevant class II 
molecule (11-13). Although early class I studies were limited 
by the nature of the binding assays (14-16), a number of re- 
cent reports  have refined the approach to measuring MHC 
class I-peptide binding and have demonstrated specificity of 
MHC class I-peptide association (17-20) and a preference for 
peptides of optimal length (21-26). Kinetic studies suggest 
significant differences occur in the association and dissocia- 
tion rates of different peptide-MHC class I complexes (21, 
25, 27), but it is unclear how these differences might affect 
peptide presentation.  Other studies have attempted to quan- 
titate the contribution of the individual peptide residues in 
peptide-MHC class I binding (23, 24, 28). In an analysis of 
the affinities of various peptides for K b, the free energy con- 
tribution of the dominant anchor side chains was found to 
be unexpectedly large suggesting a crucial role for these residues 
in specific high affinity binding (24). In contrast,  studies of 
peptide binding to HLA-A2.1 molecules found that anchor 
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binding and that secondary anchor sites played a prominent 
role in controlling the association  of peptides with class I 
molecules  (26).  It  is  not  clear,  however,  whether  these 
influences on peptide-MHC class I binding observed in vitro 
actually influence determinant selection and CTL response 
in vivo. This is largely because MHC class I-peptide binding 
studies have focussed on defined antigenic peptides or their 
analogues and have not directly correlated the peptide binding 
parameters  with the patterns of determinant selection and 
immunodominance  in the class I-restricted CTL response in 
vivo. 
To examine this relationship between the CD8 § CTL re- 
sponse in vivo and class I-peptide binding we have compared 
the H-2Kb-restricted binding and presentation of the im- 
munodominant determinant from chicken OVAzsT-~ to that 
of a newly identified subdominant determinant, OVAss-62 
derived from the same protein and restricted by the same MHC 
molecule (Kb). Our findings indicate that immunodominance 
can be accounted for by higher affinity peptide binding to 
class I molecules, which is associated with more efficient Ag 
presentation by APCs. Moreover, the differential class I-pep- 
tide binding affinities of OVA peptides are the result of ki- 
netic variation in both the association and dissociation rates 
of MHC class I-peptide complexes which are controlled by 
differences in nondominant anchor residue sites within the 
peptide Ag. 
Materiah and Methods 
Cell  Culture.  The  thymoma  cell line  EL-4 (H-2  b)  (TIB39; 
American Type Culture Collection, ILockville,  MD; 29), the TAP2 
mutant cell line RMA-S (H-2  b) (29), and the OVA-transfected 
Eb4 cell line EG7 (30) were described dsewhere. The OVAl-1 cell 
was created by transfecting the H-2Kb-expressing L cell I-3 (H- 
2  t, H-2K  b) with pAC-neo-OVA gene (30) using the calcium  phos- 
phate method. G418 (Geneticin; GIBCO BILL,  Gaithersburg, MD) 
was added to the culture to a final 0.3-0.5 mg/ml (active concen- 
tration) 24 h after transfection. Cells were then cloned by limiting 
dilution. HGPRT-negative  BW5147-Lyt2.4  cells used for hybridoma 
fusions express a neomycin resistant marker gene which maintains 
the selection of Lyt2.4 (CD8) (31). 
Cultured cell lines were grown in DMEM containing 10% FCS 
(DME-10), 5 x  10 -s M 2-ME, antibiotics, and 2/iM glutamine. 
Spleen cells were freshly prepared and irradiated with 3,000 tad 
before use as APCs. 
Priming CTL In Vitro.  CTL priming, restimutation, and "l:r 
hybridoma fusion were performed in RPMI-1640 medium con- 
taining 10% FCS (RP-10) with the same supplements as above. 
Primary CTL cultures were established by sensitizing 5  x  107 
syngeneic spleen cells from female C57BL/6  (H-2  b) mice with 
5 ￿  107 irradiated, and OVA-electroporated (2 mg/ml) spleen cells 
in an upright T-25 flask (32). After 5 d, the live responder cells 
were recovered from a Ficoll-Hypaque gradient and restimulated 
in 24-well plates at a density of 5  x  10S/well with 5-10 U/m1 
rlL-2. Each well received 2.5  x  106 irradiated spleen cells as feeders 
and the same number of electroporated stimulators. The responder 
T cells were restimulated after 5 d, and their CTL activity was 
then tested in a routine StCr-release assay. For the primed CTL 
precursor (CTLp)  t assays spleen cells (5  x  107) from C57BL/6 
mice were electroporated in the presence of 5 mg/ml native OVA. 
Cells were then washed once before intravenous injection into syn- 
geneic mice. 10 d later, in vivo primed spleen cells were titrated 
at the following cell densities: 8, 4, 2, 1, 0.5, and 0.25 x  10  s cells 
in each microtiter well with 2.5  x  10  s irradiated spleen cells as 
feeders and a similar number of OVA-electroporated (5 mg/ml) 
spleen cells as stimulators. The cultures were incubated for 8 d in 
RP-10 medium. Recombinant II.-2 was added to the cultures in 
fresh medium at a final concentration of 5-10 U/ml from day 4. 
The IL-2--containing  medium was replaced by normal medium 
12-16 h before the standard SlCr-release cytotoxicity assay  to avoid 
lymphokine-activated  killing (LAK). RMA-S cells grown at 25~ 
overnight were used as targets (33). 24 wells of each cell density 
were assayed  for cytotoxicity  on RMA-S, OVA~7_~-pulsed RMA-S 
and OVAss+2-pulsed RMA-S cells. Positive wells were scored if cy- 
totoxicity exceeded  the spontaneous  release plus three standard  devi- 
ations. The fraction of negative wells was plotted against starting 
splenic call density according to Poisson distribution to derive the 
CTLp values at 37% negative wells (34). The CTLp frequency 
values derived from this assay reflect CTL per splenocyte, noting 
that about one third of spleen ceils are T cells (35). 
T:F Hybridoma Fusion and Ag Presentation Assays.  Cell fusion 
was carried out in 42% polyethylene  glycol (PEG) (mol wt 1,500, 
BDH Chemicals, Kilsyth, Australia) and 15% DMSO. Responder 
T cells  were separated on Ficoll-Hypaque to remove  dead cells and 
cell debris, then washed and fused with BW5147-Lyt2.4 fusion 
partner cells at a ratio of 5 to 1. Approximately 24 h after fusion, 
50/~1 of 3 x  HAT medium was added to each well, and after an- 
other 24 h, 50 #1 of G418-containing HAT medium was added. 
The  final concentration  of HAT was  hypoxanthine 100  /~M, 
aminopterin 0.4/~M, and thymidine 16/~M; G418 was 0.3 mg/ml. 
Expanded clones were cocultured with OVAss4z-pulsed APCs and 
the supernatants were assayed for II.-2 using the cell line CTLL 
(36). The positive clones were also tested by assaying their dose 
responsiveness and surface  expression  of  TCR and CDS. Clone 1G8 
was the most sensitive clone obtained from the fusion (data not 
shown). For Ag presentation  assays  involving  OVA (grade  VI; Sigma 
Chemical Co., St. Louis, MO), APCs were loaded with Ag by 
electroporation, commercial liposomes, or osmotic loading as de- 
scribed (30, 32). 
Peptide Synthesis.  For initial screening of CTL activity, a set 
of OVA 15-met peptides was synthesized by the Multipin Syn- 
thesis System (Chiton Mimotopes, Clayton, Australia;  37) and dis- 
solved in DMSO at about 1 mM. All other octamer peptides were 
assembled on a peptide synthesizer (model 431A; Applied Bio- 
systems, Foster City, CA), using highly optimized tert-butyloxy- 
carbonyl) (t-Boc) solid phase synthesis chemistry protocols. The 
peptides were deproteeted and cleaved  from PAlM  resin using stan- 
dard high-fluoride (HF)  methods, followed by extraction into 
10-30% acetic acid. OVA2s7-~4, OVAss-62, OVAp.+2, OVA2sT-2+4-cr, 
OVAss42-c+, OVA~s?-264-c4, and OVAss~2-c4 were purified to >95% 
purity by semipreparative reverse phase HPI.C using an Aquapore 
C8 column on a high performance  liquid chromatographer (model 
160A; Applied Biosystems). Final characterization and assessment 
of purity was achieved  by reverse phase HPLC or by capillary  dec_ 
trophoresis (model 270A; Applied Biosystems). All peptides and 
1 Abbreviations used in this  paper: BFA,  brefeldin  A; CTLp,  CTL precursor; 
ER., endoplasmic  reticulum; HBST, Hepes Buffered  Saline  Twcen; SPR, 
surface plasmon resonance. 
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kept at  -20~ 
Peptide Binding to K s on RMA-S Cells.  Relative peptide binding 
to H-2K  b was assessed by measuring the folding and stabilization 
of K b on the surface of RMA-S cells after culture in medium con- 
raining the appropriate peptides (17, 38, 39). RMA-S cells (3  x 
10  s) were incubated at 25~  for 12-14 h in 400 #1 DME-10 and 
graded concentrations of peptides were added for the last 60 rain 
before transfer of the cells to 37~  for 2 h to allow the "empty" 
molecules to disappear  from the call surface. The ceils were then 
harvested and stained on ice using a conformational Kb-specific an- 
tibody,  Y3 (17), or an c~l-domain-specific antibody, 20.8.4 (40) 
and analyzed by FACScan  |  (Becton Dickinson & Co., Mountain 
View, CA). Peptide binding to K b resulted in a proportional in- 
crease in mean channel fluorescence of mAb staining. To estimate 
the relative dissociation rates of peptides bound to RMA-S cells, 
these cells were set up in  12-well plates at a density of 1.2  x 
106/ml in the presence or absence of 10 #M peptides for 12 h at 
25~  Brefeldin A (BFA) (10 #g/ml) was added to the cultures 
for the last 2.5 h to prevent the appearance  of newly synthesized 
class I molecules (41). The cells were then washed with prewarmed 
medium, before being aliquoted into 0.3-ml volumes of DME-10 
containing 10 #g/ml BFA and subsequently transferred to a 37~ 
incubator. This time point was  taken as time zero. At different 
time points afterwards,  samples were collected and directly stained 
for Kb-peptide complexes on the cell surface with mAb 20.8.4. 
RMA-S cells cultured under the same conditions but with BFA 
continuously present in the medium were also studied. BFA in- 
hibits the egress of newly synthesized class I molecules from the 
endoplasmic reti~lum  (EK) to the cell membrane (41). 
Flow Cytomet~  Ceils were harvested and washed in PBS. These 
ceils (3  x  l0  s) were then incubated with either 100 #1 of PBS 
containing 5% FCS or mAb culture supernatants for 30 min on 
ice. Washed cells were then incubated with fluoresceinated  sheep 
anti-mouse Ig (Silenus Labs. Pty., Ltd., Hawthorn, Victoria, Aus- 
tralia),  washed in PBS, and resuspended in FACS  |  fixative con- 
raining 1% paraformaldehyde and 0.02% azide (0.15-0.2 ml/tube~. 
For each histogram, 10,000 viable cells were counted on a FACScan  ~. 
Peptide Competition Assays.  Both OVA~7-z64 and OVAss~2 pep- 
tides were freshly diluted from stock solutions to "~3  x  10-11 M 
in DMEM free of FCS as stimulator peptides.  These solutions were 
then used as solvent to dilute the competitor peptides to various 
concentrations ranging from 10 -s to 10 -'s M. I-3 cells were set 
up in 96-well plates at 2  x  10Vwell in DME-10 overnight. The 
overnight medium was completely removed and 50 #1 of stimu- 
lator/competitor peptide mixture was added to each well. Cells were 
pulsed for 30 rain at 370C in a CO2 incubator. Then the peptide 
mixture was removed and the cells were washed three times with 
serum-free DMEM. T hybridoma cells (10  s) were added into each 
well and supernatants from a 24-h coculture were then assayed for 
IL-2 content. 
MHC Class IMolecules.  The engineered, soluble mutine MHC 
class I molecule H-2Kb, was produced in transfected L cells and 
purified by immunoaffmity chromatography as described previously 
(42). To increase the peptide binding capacity,  H-2Kb~ was emp- 
tied of endogenous peptides by exposure to pH 12.5, 0.2 M potas- 
sium phosphate buffer for 10 rain on ice and was neutralized by 
centrifugation through a column (Bio-Spin 6; Bio-Rad Laborato- 
ries, Richmond, CA) equilibrated with 20 mM Hepes, pH 7.3, 
0.15  M  NaC1,  3.4  mM EDTA,  and 0.005%  Tween-20 (Hepes 
Buffered Saline Tween [HBST]). 
Surface Plasmon Resonance.  For real time binding experiments, 
a biosensor system (BIAcoreTM; Pharmacia Biosensor,  Piscataway, 
NJ) was used (43). Binding of soluble macromolecules to a ligand 
immobilized on a dextran-gold surface results in changes in the 
surface plasmon resonance (SPK) signal recorded in real dine. All 
biosensor binding experiments were carried out in HBST buffer. 
Details of the use of the biosensor system to detect peptide-MHC 
interaction have been described elsewhere (20). The analogues of 
the OVA-derived peptides substituted with cysteine at position 6 
(OVA~7-a,,~cr, SIINFCKL and OVAs~2-c~, KVVKFCKL) were 
immobilized to the carboxymethyl dextran surface of the biosensor 
using a slightly modified approach described previously as Method 
D (20). 
SPR  Binding Experiments.  Soluble,  immunoaffinity purified 
H-2Kb~ molecules were diluted to concentrations between 0.625 
#M (39 #g/ml) and 5 #M (312.5 #g/ml) in HBST and exposed 
to the peptide-modified surfaces. After each binding cycle, the sur- 
face was regenerated by injection of 50 mM phosphoric acid for 
30 s. For the association rate analysis, 40 #1 oftbe protein solution 
was injected at a flow rate of 5 #l/rain. For the dissociation rate 
measurement, 40 #1 of the H-2Kb, solution was injected at 1 #1/ 
rain to load the peptide surface,  and the dissociation phase  was 
carried out by injection of HBST at  100 #l/rain for a period of 
80 rain. The SPK signal obtained in each binding cycle was recorded 
as a real time pattern with a sampling interval of 0.2--0.5 s plotted 
in resonance units  (KU) versus  time.  This plot is known as a 
"sensorgram" 
Estimation of  Kinetic Rate Constantx  The sensorgrams were trans- 
ferred as text flies to a Macintosh computer (model IIfx; Apple 
Computer, Inc., Cupertino, CA) and curve ftting was performed 
using IGOK Graphing and Data Analysis software (WaveMetrics, 
lake Oswego, OK). The baseline of  each sensorgram was corrected 
by subtraction of the SPK signal before the injection of the pro- 
rein. For determination of the association rate constant, the associ- 
ation phase of the sensorgram was fitted to a double exponential 
formula: Bt  =, Btot -  Bmprot[exp(-kloht)]  -  Bmbuf[exp(-k2~t)], 
where Bmprot corresponds to maximal protein binding available, 
and klob, to a product of the kinetic association  rate constant, k~ 
and the concentration of empty molecules of H-2Kb,, c. Formally, 
kloh  s  K~ c +  kaa, but in this case, since kdi, is <<k,, c, it does 
not significantly influence the fit (see Results). The second exponen- 
tial term was introduced to compensate for the rapid rise of the 
resonance signal during the first seconds of the injection as a result 
of the buffer change. For each of the peptide surfaces, klob, values 
were obtained at three different H-2K  b, concentrations and plotted 
as a function of the concentration. The slope of this graph was 
taken as the kinetic association rate constant, k,,. The dissociation 
part of the sensorgrams was fitted to the double exponential equa- 
tion: B,  =  /3o  a't exp(-kdj" t)  +  Bo  ~~  exp(-k~/l~  0, where Bt 
corresponds to binding (in Kid) at time t. Assuming two classes 
of dissociating complexes,/3o for each class corresponds  to binding 
at time zero, and k,s to the kinetic dissociation rate constant (s-1), 
whereas "fast" and "slow" indicate the two kinetic classes. 
Results 
OVA-specific  CTLs Recognize Multiple OVA  Determinants 
in H-2  b Mice  In H-2  b mice challenged with OVA by cross- 
priming (44), osmotic loading of cells with OVA (45) or im- 
munization with the EL-40VA-transfectant EG7, the OVA- 
specific CTL response is dominated by T  cells specific for 
OVA2sl-264 (30,  44,  and data not shown).  However, when 
1473  Chen et al. mice were immunized by injection of spleen cells electropo- 
rated with a high concentration (2 mg/ml, 45/tM) of freshly 
prepared native OVA, it was noticed that not all the CTL 
response could be accounted for by the OVA257-264 deter- 
minant (data not shown). A  similar observation was made 
when OVA-specific  CTL lines were primed in vitro by repeated 
stimulation of naive T cells using spleen cells loaded by elec- 
troporation with native OVA (Fig. 1 A). As shown in Fig. 
1 A, T  cells stimulated in this way were more effective at 
killing the OVA-transfectant  EG7 than in killing EL-4 cells 
sensitized  with OVA2s7-264 peptide. This observation sug- 
gested the existence of CTLs recognizing additional OVA 
epitope(s) which were induced by delivering higher concen- 
trations of OVA than used in other immunization protocols. 
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Figure  1.  Identification of a new OVA determinant and comparison 
of CTLp frequencies. (A) 5  x  107 C57BL/6 spleen cells were cocultured 
with 5  x  107 irradiated syngeneic spleen cells loaded with 2 mg/ml OVA 
by electroporation in an upright T-25 flask. 5 d later the live cells were 
restimulated with the same APCs in the presence of 5 U/ml ri1:2 in 24- 
well plates. 5 d after the second restimulation,  a 3.5-h slCr-release assay 
was performed on EL-4 (11), EL-4  plus 0.5 #M OVA2s7-~ (1"3), and OVA 
transfected EL-4 cell line EG7 (@). (B) A long-term CTL line from (A) 
was tested for cytotoxicity on EL-4  (11) or Eb4 plus 0.5 #M of the peptide 
OVAzs3-276  ([1"1),  OVA10-24  ([-]),  OVAs3-67  (/~),  OVA174q88  ([~),  or 
OVA2ss-~9 (~). (C) For primed CTLp estimation, irradiated spleen cells 
(5  x  10  7) loaded with 5 mg/ml OVA by electroporation were reinjected 
intravenously into syngeneic mice. 10 d later the primed spleen cells were 
restimulated in microtiter plates at varying cell densities with 2.5  x  10  s 
electroporated (5 mg/ml OVA) APCs as stimulators and the same number 
of irradiated spleen cells as feeders. 4 d later, 5 U/ml rib2 was added into 
the culture and the medium was renewed. Replicates  were assayed  by directly 
adding 104 51Cr-labeled RMA-S with 0.5  /~M of OVA257-264, 0.5  #M 
OVAss-62, or without peptides in round-bottom plates. The CTLp fre- 
quencies were then determined  as described in Materials and Methods. 
(D) To demonstrate  the specifidty and sensitivity of the T  hybridomas 
GA4.2 and 1G8, I-3 cells (2  x  104) were pulsed with graded concentra- 
tions of peptides in 50/~1 of FCS-free medium for 60 min at 37~  The 
peptide-containing medium was then removed and the cells were washed 
three  times  with  medium before  either  GA4.2  (OVA2s7-264) or  1G8 
(OVAss-62) hybridoma cells (105) were added. II:2 released in the super- 
natants was measured by CTLL after 24 h. Each point represents the mean 
value of triplicate assays. 
In addition to the well-recognized OVA257-264  determinant, 
at  least  five  other  peptide  sequences  containing the  K b- 
binding motif (x x x x F/Y x x L) proposed by Falk et al. (1) 
occur within the OVA Ag. These include OVAnq9 (CFD- 
VFKEL), OVAzs-32 (ENIFYCPI), OVAss-6z (KVVILFDKL), 
OVAt07-114 (AEEKYPIL), and OVA176-183 (NAIVFKGL). A 
number of these peptides were therefore synthesized as 15- 
met and tested for CTL recognition by addition to SlCr- 
labeled APCs. Although we expected that the optimal K b- 
restricted peptides would be eight or nine residues in length, 
we felt that extracellular proteolysis would allow the evalua- 
tion of longer precursor peptides in initial screening for CTL 
activity.  The reactivity of one CTL line was specific for a 
determinant contained in  the  synthetic peptide OVAs3-67 
(Fig.  1 B),  however CTLs recognizing other OVA deter- 
minants also may have been present within some uncloned 
CTL lines (data not shown). A simple explanation for the 
immunodominance of OVAzs7-~4 would be a  higher fre- 
quency of CTLs capable of recognizing this determin2nt com- 
pared with other OVA peptides.  To assess this possibility, 
the  primed  precursor  frequencies  of  CTLs  recognizing 
OVAss-62 and OVA257-~4 were examined after immunization 
of H-2  b mice with  OVA-electroporated syngeneic spleen 
cells. As shown in Fig.  1 C, the primed CTLp frequency 
in spleen cells from mice immunized with native OVA in 
vivo and restimulated under limiting dilution conditions in 
vitro, was similar for the OVA257-264 and OVAss-62 deter- 
minants (average result,  10-SApleen cell or '~2.5  x  10-4/T 
cell). Therefore the differences in the relative immunogenicity 
of OVA2sT-~ and OVAss-62 were not  due to  an  obvious 
difference in the precursor repertoire of T cells reactive with 
these two determinants. 
To evaluate presentation of the two OVA determinants in 
more  detail,  CTLs  were  fused  to  the  CD8 +,  "TCR- 
o~-/B-" fusion-partner BW5147 and cloned T hybridomas 
which recognized Kb/OVAss_62 were compared with the T 
hybridoma GA4.2, known to be specific for Kb/OVA257-264 
(46). One such T hybridoma, 1G8, was compared with GA4,2, 
as shown in Fig.  1 D.  The 50%  maximum IL-2 response 
of GA4.2  occurred at  "~50 pmol of synthetic OVA257-264 
similar to the concentration of synthetic OVAss-62 required 
for 50% maximum response of the hybridoma 1G8 (Fig. 1 D). 
Although most H-2Kb-restricted peptide fragments are 
octamers (1), some preferred peptides are nonamers (47). The 
OVAzs7-~4 peptide is known to be the optimal length of this 
determinant for K b association  (23, 46) as well as the pep- 
tide that is naturally presented by K b molecules after OVA 
processing (48).  The  OVAss-62  peptide was  the preferred 
length for antigenicity of this determinant since lengthening 
of Kb-restricted peptides at the COOH terminus, and using 
peptides with longer or shorter NH2 termini, resulted in 
one or more orders of magnitude impairment in stimulation 
by the T  hybridoma 1G8 (data not shown) and in binding 
K b molecules on IkMA-S (data not shown, and see Fig. 4 
B). We conclude that OVAss-62 is the most likely naturally 
presented peptide derived from the OVAs3-67 determinant. 
Presentation of OVA2sT-26, Is More E~cient  than  OVA ss-62. 
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(Kb/OVAss_62) and GA4.2  (Kb/OVA2s7_264) were quantita- 
tively similar in experiments using synthetic peptides, rela- 
tive differences in their activation on Ag-pulsed cells could 
conveniently be used to compare the relative presentation of 
OVA2sT-264 and OVAss-~2 after natural Ag processing. These 
T  hybridomas were therefore used to examine the natural 
appearance  of the  OVA2s~-264 and  OVAss-6~ determinants 
after the loading of native OVA into the cytoplasm of K b- 
expressing APCs.  It was previously shown (32)  that OVA 
can be introduced into the cytoplasm of APCs by electropo- 
ration of cells in the presence of native OVA. Thus, splenic 
(Fig.  2 A) and L cell (Fig.  2 B) APCs were electroporated 
with graded amounts of freshly prepared native OVA, washed, 
and then cultured with GA4.2 or 1G8 for 24 h. Ag presenta- 
tion was assessed by IL-2 production of the activated T hy- 
bridomas.  To achieve 50%  maximum activation of 1G8 it 
was necessary to load APCs with up to 50-fold higher con- 
centrations of native OVA than required to give 50% max- 
imum activation of GA4.2 (15 compared with 0.3 mg/ml, 
Fig.  2,  A  and B).  Thus,  the OVA257-264 determinant was 
processed and/or presented up to 50 times more efficiently 
than the OVAs~2 determinant after the cytoplasmic loading 
of native OVA. Ag presentation required cytoplasmic loading 
and  processing  of intact  OVA  and  was  not  due  to  con- 
taminating peptide fragments because APCs either pulsed with 
20 mg/ml of OVA and then washed (Fig. 2 B), or electropo- 
rated in the presence of the same amount of OVA and washed 
before fixation with 1% paraformaldehyde (49) (Fig.  2 A), 
did not  stimulate either T  hybridoma.  The difference in 
efficiency of presentation between OVA257-264 and OVA55-62 
was between 20- and 50-fold in several types of APCs (in- 
cluding EL-4 cells; data not shown) and was also evident when 
OVA was introduced into APCs by different methods (e.g., 
by liposomes and osmotic loading; data not shown). In addi- 
tion, neither the EL-40VA-transfected cell line EG7, nor 
the OVA-transfected Kb-expressing  L  cell (OVAl-l)  acti- 
vated the T hybridoma 1G8, despite activation of hybridoma 
GA4.2 by both of these cell lines (Fig.  2 C).  Presumably, 
the level of Kb/OVAss-62 expression by these OVA-expressing 
APCs was below the threshold for recognition by the T hy- 
bridoma 1G8,  as suggested by the dose-response curves in 
Fig.  2, A  and B. 
Differences in the level of presentation of the OVAss-62 
and OVA2sT-264 determinants might reflect differential Ag 
processing, peptide half-life, selective peptide importation into 
the ER/pre-Golgi,  or differences in the affnity of peptide 
association  with H-2K  b. Therefore, differences in the associ- 
ation of the two peptides with H-2K  b were evaluated to see 
if they could account for the differential Ag presentation of 
these determinants. 
OVAss~sz Associates much Less E~ciently with H-2K  b than 
OVAzsT-z64.  The ability of OVAs~2 and OVA2sT-264 to as- 
sociate with H-2K  b was examined by several methods. First, 
the capacity of the two synthetic peptide determinants to 
reciprocally inhibit T cell recognition was tested in functional 
assays using the hybridomas 1G8 and GA4.2 as reporters of 
Kb-peptide association.  APCs  were pulsed for 60  min at 
37~  (in the absence of FCS) with the mixture of reporter 
peptide (~30 pmol) and graded concentrations of the com- 
petitor peptide to estimate the concentration required for 50% 
inhibition of the reporter response (Fig. 3, A and B). In sev- 
eral independent experiments, the concentration of OVAs~2 
needed to inhibit the response of GA4.2 to APC pulsed with 
OVA2s?_~  was  ~2  x  10 -7 M.  In  contrast,  in  the same 
experiments the concentration of OVA2sT-264 needed to in- 
hibit the response of 1G8 to APC pulsed with OVAs~2 was 
~3  x  10-9 M. Thus, OVAz57-~ was considerably more eff- 
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Figure  2.  Presentation of OVA2sr  derived from native 
OVA is more efficient than OVAss-62. Irradiated spleen ceils 
(A), and I-3 calls (B), were  electroporated  in the presence  of 
graded concentrations  of native OVA at 250/~F and 0.45 kV. 
The cells were then washed and assayed with 10  s T hy- 
bridoma cells and 10  s APC. Either 20 mg/ml OVA-pulsed 
APCs without dectroporation  (B), or APCs electroporated 
in the presence of 20 mg/ml OVA, then washed  and fixed 
by 1% paraformaldehyde  (A), were used to control for con- 
taminating peptides or effects of electroporation on OVA 
antigen. Similar results were obtained with varying APC 
numbers. (C) 10  s 1G8 (open  syrabo/s)  or GA4.2 (closed  symbols) 
cells  were  cocultured  with I-3 (triangles), OVA-transfected  I-3 
(circles), or OVA-transfected  EL-4 (squares)  at various  APC den- 
sities. Each  point represents  the mean  value  of  triplicate  assays. 
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Figure 3.  OVAss-62  is less et~cient at competing OVA2sT-~ than vice 
versa. Either OVAss-~2 (tl) or OVA257-264  (B) was used to sensitize APCs 
at a final concentration of '~3 x  10-11 M as stimuhtor peptide in DMEM 
free of FCS, with competitor peptide present at a range of concentrations 
as shown on the x-axis. The peptide mixture was directly added to I-3 
cells in 96-well plates for 60 min at 37~  and the cells were washed three 
times before the addition of 10  s of either hybridoma to each well. Pep- 
tide competition was assayed  by activation of the T hybridomas 1G8 ([7) 
and GA4.2 (ll) after 24 h. The Ib2 content of the supernatants was mea- 
sured by CTLL proliferation. Each point represents the mean value from 
duplicate assays and the complete experiment was repeated three times. 
The 50% inhibition concentration for each peptide is indicated with an 
arrow. 
cient (60-70-fold) at competing recognition of Kb/OVAss-62 
than vice versa. 
The ability of the two OVA peptides to stabilize surface 
expression of H-2K  b on the mutant APC RMA-S was then 
examined. The RMA-S cell line has defective TAP function 
and so fails to properly load class I molecules with peptide 
Ags derived from the cytoplasm. The association of peptide 
with  thermolabile,  empty-K  b  molecules  stabilizes these 
structures and results in an increase in the recognizable level 
of K  b on  the cell surface of RMA-S which can then be 
stained by al/o~2 conformation-dependent mAbs such as Y-3 
or 20.8.4 (17, 38, 39). This assay was used to quantitate the 
binding of the OVAzs7-~4 and OVA55-62 peptides to K  b on 
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live RMA-S (Fig. 4). RMA-S cells were grown at 25~  over- 
night to induce high levels of empty K  b molecules which 
were then stabilized by pulsing with graded concentrations 
of the two OVA peptides. OVA-peptide binding to K  b was 
evident for both peptides with the 50%  maximum values 
being •2.5  x  10 -s M for OVAzsT-~, and ~10 -6 M for 
OVAs~2 (Fig. 4 A). The differences in Kb-binding between 
the two synthetic peptides  at 25~  was not the rest& of 
differential sensitivity to proteases in FCS since the functional 
activity of free peptide recovered at the completion of the 
assays (at 25~  was similar for the two peptides (data not 
shown). The same relative Kb-peptide binding of OVA pep- 
tides was observed with independent Kb-specific mAb (in- 
cluding mAb Y-3 and 20.8.4) at 25~  indicating that the 
differences in peptide-K  b association were not an artefact 
due to peptide-specific  mAb (50-52). OVAs4-62 and OVAu,-62 
peptides were even less efficient at associating with H-2K  b 
on RMA-S cells at 25~  consistent with the conclusion that 
OVAs~2 is the optimal length of the determinant for K  b- 
binding (Fig. 4 B). Taken together, the peptide competition 
and epitope induction/stabilization  data suggested that the 
relative affinity of the Kb/OVA2sr  complex was around 
50-fold higher than that of the Kb/OVAss-62 complex. 
Differential Kb/OVA PeFtide Binding Is Due to Kinetic Differ- 
ences in both Association  and Dissociation Rates.  Variation in 
peptide--class I affinity has previously correlated with differ- 
ences in dissociation rates of these complexes (21). Therefore, 
we estimated  the rdative rate of dissociation  of Kb/OVA 
peptides by measuring the kinetic disappearance of antibody- 
reactive-K  b complexes  on  RMA-S  formed overnight  at 
25~  then washed of free peptide before being returned to 
37~  To minimize the effect of newly synthesized K  b mol- 
ecules appearing on the call surface during the decay period 
at 37~  the RMA-S cells were cuhured in the presence of 
BFA for the last 2.5 h of the peptide incubation  and after 
the removal  of  peptides (41). BFA is an antifungal agent known 
to prevent the transport of newly synthesized class I mole- 
cules through the vacuolar compartment (53), As shown in 
Fig. 4 C, the tl/2 for loss of empty-K  b expression at 37~ 
in the absence of any added peptide was <80 rain whereas 
the tl/2 for K b molecules stabilized by OVA257-264 was "~470 
min and for those stabilized by OVAss-62, "~160 min. Thus, 
at 37~  peptide complexes of Kb/OVAss-62 were lost from 
the cell surface of RMA-S at a rate two- to three times faster 
than complexes of Kb/OVA2sT-264.  This estimated difference 
in stability  between Kb/OVAss-62 and Kb/OVA257_264  sug- 
gested that there must also be a significant difference in the 
association rate of the two peptides in order to fully account 
for the differences  in presentation and epitope induction/stabili- 
zation  of these two determinants.  To test this  hypothesis, 
we used a real time biosensor assay for measuring binding 
of OVAss-62 and OVA2sT-264 analogues to soluble secreted K  b 
molecules (H-2Kb,) depleted of bound peptides by exposure 
to  pH  12.5 (20). In  this  assay, OVA  peptide  analogues 
SIINFCKL (OVA257-264--c6)  and KVVRFCKL (OVA55-62-c6) 
were coupled to a biosensor dextran-modified gold surface 
as previously described (20). The peptide residue at position 
6 was chosen for Cys substitution  because the side chain at 
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Figure 4.  OVAz~7-~,4  stabilizes K  ~ more efficiently than 
OVAs~-62. RMA-S cells (3  x  l0  s) were cultured in 24-well 
plates overnight (12-14  h) at 25"C and the indicated peptides 
were added for the last 60 rain (A and B). The cells were 
then transferred to 37"C for 2 h and stained with an otl/ot2 
conformational  mAb, Y3, and a FITC-labeled  second  Ab. (C) 
RMA-S cells (1.2 x  10~) were cultured at 250C for 12 h in 
12-well plates in the presence of 10/~M OVAz57-x,~ (11), 
OVAs~-rz (~), or in the absence of peptides, with (~) or 
without BFA (O). BFA (10/+g/ml) was added to all cultures 
for the last 2.5 h. The cells were then washed with prewarmed 
medium, aliquoted into 24-well  phtes in 0.3 ml DME-10  con- 
mining 10/~g/ml BFA, and transferred to 370C. The transfer 
point was taken as time zero. Cell aliquots were sampled at 
different time points and stained as described above. 
this  position  is  known  to be  solvent  exposed  rather  than 
directly  engaged  in  Kb-binding.  H-2K  b,  injected  into  the 
flow chamber results in Kb,-peptide binding at the dextran- 
modified gold surface which can be recorded instantaneously 
by a SPR detector. Plasmon resonance represents changes in 
the angle of complete internal reflectance of polarized light 
incident on the opposite surface of the gold film and is propor- 
tional to the mass of the material binding the modified surface. 
The  kinetic  sensorgrams  of  binding  of  H-2Kh,  to 
OVA2sT-264-c6- and OVAss-6z-cr-modified biosensor surfaces 
are shown in Fig. 5. Binding experiments were carried out 
at  three concentrations  of H-2Kb~ and  revealed significant 
kinetic  differences  in  the  association  of  H-2Kb~  with 
OVA2sT-264-c6 (Fig. 5, A  and C) compared with OVAs~2-c6 
(Fig. 5, B and C). The OVA2sT-264 analogue associated with 
an estimated  Ko~ of 5.9  x  103 M -t s -1 at 25"C whereas 
the OVAss-62 analogue showed much slower binding to Kb~ 
with an estimated Ko, of 6.5  x  102 M- 1 s- t.  The associa- 
tion  of Kb+  with  the  OVA2sT-264 analogue  was  biphasic 
whereas binding of the OVAss-62 analogue was monophasic 
(compare Fig. 5, A  and B). The reason for the apparent biphasic 
association of H-2Kb~  with OVA~sT-26~:~ is not dear,  how- 
1000 
5OO 
==  o 
| 
looo  m 
A 
1.25 ltM 
~  0.625 gM 
F  SIINFCKL 
t 
I  I  I  I,  I  I  I 
B 
/"'"~'tp  5 pM 
j~'~'~  1.25 gM 
0  200  400  600 
Time ( sec ) 
1477 
0.02 
0.01 
1500 
Chen et al. 
C  ~lxFOq. 
P 
/ 
S  /, 
/S 
0" 
l  l  i  ,  l  l  I 
2  4  6 
H-2K  b ( ~tM ) 
D 
t  KVVRFCKL 
t  ,  I  I  I 
0  2000  4000 
DissodalJon time ( sec ) 
Figure  5.  Measurement of Kb/peptide association 
and dissociation rate constants using SPR detection. 
H-2K  b, (0.625-5/zM) was injected over  biosensor sur- 
faces modified with SIINFCKL (OVA~7-x,+-c~) (A) 
or KWRFCKI. (OVAss-rz~) (B) for 8 min at a flow 
rate of 5 pl/min.  ( ~ ) Initiation of injection of the 
protein. ( ~ ) Beginning of the buffer washout phase. 
Data points were curve  fitted, as described  in Materials 
and Methods. Values of Klo~ were plotted versus 
H-2K  b, concentration (C), and curve fitted to a simple 
linear relationship, y  =mx +  b, in which m =  k, 
in units of M - 1 s - 1, and b = k~i, obs, in'units of s- 1. 
Values for curve  fitting are displayed. For measurement 
of  dissociation rate constant using surface  plasmon res- 
onance detection (/3), H-2Kb, (1.6/~M) was injected 
for 40 min at a flow rate of I #l/ml over biosensor 
surfaces modified with SIINFCKL (OVA~7-2~.--c6)  or 
KWRFCKL (OVAss~z-cr) to apparent saturation, 
and the dissociation  phase was followed  during buffer 
washout at a flow rate of 100/~l/min, (~  ~ ) Begin- 
ning of  protein and washout phases as d~'nlx~l above. 
Da~ points were fitted to the double exponential decay 
equation as described in Materials and Methods. The 
dissociation kinetic rate constants obtained for the 
pt~aih'ng (slow) components  are indicated in the text. ever similar biphasic binding patterns have been observed for 
other MHC class I-peptide combinations (Khilko, S., and 
D.  H.  Margulies,  unpublished results).  Rapid MHC class 
I-peptide binding may occur with empty molecules, whereas 
slower binding could involve displacement of residual  en- 
dogenously derived peptides from K  b molecules (54). Alter- 
natively, biphasic binding might reflect peptide association 
with class I molecules at different stages of assembly with 
B2-microglobulin. 
The data  demonstrate that  H-2Kbs was  about  10-fold 
faster  at  associating  with  OVA2s7-264-c6 compared  with 
OVA55-62-C6. This trend was  preserved  in binding experi- 
ments performed at 37~  though measurements at the higher 
temperature were complicated by a time-dependent denatu- 
ration of the protein (data not shown). These estimates of 
the association rate constants are of course dependent on the 
assumption that the H-2Kbs protein preparations are com- 
pletely active, that all binding sites are available for peptide 
binding, and that the C6-substituted analogues are represen- 
tative of their parent peptides. The C6-substituted analogues 
stabilized  K b expression  on RMA-S cells with equivalent 
efficiency to the wild-type peptides (data not shown), con- 
sistent with these analogues being closely representative  of 
their parent peptides.  Competitive inhibition in SPR bind- 
ing assays also indicated that OVAss-62-c6 was equivalent to 
OVAss-62 in associating with H-2Kbs, however H-2K  b, was 
slightly less effective at binding OVA2~7-2/~c6 than wild-type 
OVA2s7-264 (about twofold less). Thus, any discrepancy be- 
tween the behavior of the C6-analogues and their parent se- 
quences might serve to slightly underestimate the relative 
difference in KbffOVA2ST_~4  and Kb~/OVAs~2 affinity con- 
stants  in the solid phase SPR binding assay. 
Kinetic dissociation of the KbffOVA peptide analogues 
was measured at 25~  by washing out the Kb~ molecules 
after aUowing Kb~-peptide binding to reach saturation (Fig. 
5 D). The results indicated that KbffOVA2s7_~4_c6  dissociated 
with a Koff =  9.1  x  10 -6 s -1 corresponding to a tl/2  = 
1,270 min whereas for KbffOVAss-62-c6 the Koff =  1.6  x 
10 -s s  -1 corresponding to a tl/2  ---  720 min. These rela- 
tive dissociation rates  (Kbs/OVAs5-62_c6 Koff about twofold 
faster than Kbs/OVA2s7-264-c6) were consistent with the rel- 
ative tl/~ of surface Kb-peptide complexes determined in the 
RMA-S binding experiments shown in Fig. 4 C. An inde- 
pendent set of experiments using a different preparation of 
H-2K  b, and with either OVA2s7-264.-c4  or OVAss-62-c4 peptides 
immobilized on the biosensor surface,  also indicated that 
OVAss-62 associated more slowly and formed less stable com- 
plexes with H-2Kb~ than OVAzsT-~ (data not shown). Thus, 
the  biosensor  studies  demonstrate  that  the  20-50-fold 
difference  in  presentation  and  Kb-stabilization  between 
OVA2s7-z64 compared with OVAss-62 could be substantially 
accounted for  by  differences  in  both  kinetic  association 
(Kb,/OVA2sT_Z64-~ >--10-fold faster than KbffOVAss-62_c6) as 
well as kinetic dissociation (KbffOVAss-62-0s >~twofold faster 
than KbffOVA2s~_264-c6). 
Multiple Peptide Residues As 14~II  As Dominant Anchor Residues 
Contribute to Class I-Peptide Association.  Despite significant 
differences in Kb-binding of the OVAs~z and OVA~7-~ pep- 
tides, the sequences of these determinants contain very similar 
residues especially in the COOH-terminal half (OVA2s7-z64, 
SIINFEKL versus OVAss-62, KVVILFDKL) where the K  b- 
binding motif residues 5F and 8L are located (1). In previous 
studies of Kb-peptide binding, P5 and P8 have been shown 
to be important for binding (33,  39),  consistent with the 
observation that these residues  are buried within the K b- 
binding deft  (55,  56).  Because the  amino acids in  these 
positions are identical between OVAz57-~ and OVAss-62, we 
assumed the differences in their binding affinity for K b must 
be due to other residues within the peptide sequences. Notably, 
the peptide residue at position 2 (or 3) has recently been 
suggested as another potential anchor site for Kb-binding 
(24). Therefore, to further evaluate the influence of individual 
residues in the interaction of the two OVA peptides with 
H-2K  b, reciprocally substituted peptide analogues of OVAss-62 
and OVA2sT-264  were studied in RMA-S stabilization  assays 
and competitively in T  hybridoma activation assays. Table 
1 shows the sequences of the wild-type peptides and their 
substituted analogues. The relative efficiency of Kb-peptide 
association is shown by normalizing the half-maximal peptide 
concentrations of each wild-type peptide to give a relative 
binding efficiency  of 1. All peptide analogues containing single 
substitutions in the direction of OVAs~2 -~ OVAz57-~ were 
capable of stabilizing K b on RMA-S cells at 25~  The sub- 
stitutions of OVAss-62 ~  OVAzs7-264 at PLK -~ S, P2V 
I, P4K ~  N, and P6D -~ E all resulted in Kb-stabilization 
which was siguificantly greater than that obtained with the 
parent peptide OVAss-62 at 25~  By contrast, substitution 
of OVAss-62 "-~ OVA2s7-264 at P3V -~ I did not enhance K b 
stabilization  relative  to the parent peptide OVAss-62.  The 
single most influential change in OVAss-62 was the relatively 
conservative substitution P6D -~ E (OVAss-62  ~  OVA257-264) 
which resulted in  10-fold  improvement in Kb-binding at 
25~  relative to OVAss-62. All of the peptide analogues in 
the set  OVAss-62 ~  OVA257-264 showed some Kb-stabiliz  - 
ing ability at 37~  which was not evident for wild-type 
OVAss-~2 under similar  conditions. 
Substituted analogues  in the direction of OVA257-264 --" 
OVAss-62 showed  little  or  marginal  impairment  of  K  b- 
binding evident at 37~  and all analogues from this set were 
still  able  to  associate  with  K b more efficiently  than  the 
OVAss-62 peptide. The OVAz57-264 -'~ OVAss-62 substitution 
P6E ~  D  was most disruptive for K b binding requiring 
fivefold higher concentrations of peptide than the OVAzs7-~64 
parent for 50%  maximum binding at 25~ 
The OVAss-62 ~  OVA2s7-~64 analogues which were most 
efficient at stabilizing K b expression on RMA-S cells were 
also more effective than the OVAs~2 parent peptide in com- 
peting T hybfidoma recognition of OVAzsT-~ reporter pep- 
tide (data not shown). Collectively,  these findings indicate 
that amino acids other than the previously defined "anchor" 
residues, 5F and 8L, strongly influence the affinity of pep- 
tide-K  b association. 
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One of the most intriguing questions arising from studies 
of class I-restricted immune responses is why so few peptide 
determinants are selected for recognition by CTLs despite 
the presence of other putative antigenic peptides within the 
same Ags (57-59). Even CTLs recognizing complex viral com- 
ponents including relatively large proteins  such as envelope 
glycoproteins  (60, 61), tend to focus the immune response 
on a small number of peptide determinants, leading to im- 
munodominance  of these peptides. Very little is known about 
the factors that influence immunodominance  in the class I-re- 
stricted response, whereas the major influences  on determinant 
selection and immunodominance in class II-restricted immune 
responses include the affinity of peptide-MHC association 
(11-13), differential Ag processing (62), and the presence of 
apparent holes in the T cell repertoire (13, 63). The stringent 
requirements for MHC class I-peptide binding (20, 25-27, 
55,  56, 64-66) suggest  that determinant selection in class 
I-restricted immune responses might be strongly influenced 
by the nature and strength of MHC class I-peptide binding. 
In this report we have compared the H-2Kb-restricted bind- 
ing and presentation  of the immunodominant OVA257-~64 
(SIINFEKL) determinant to a subdominant OVA determinant, 
OVAss-62 (KVVlkFDKL).  The novel feature of this study is 
the correlation between the hierarchical specificity of the in 
vivo class I-restricted response to OVA with the subsequent 
hierarchy of Ag presentation  and the kinetic and biochem- 
ical details of Kb-peptide binding. 
The mature immune response to OVA in H-2  b mice is 
dominated by CTLs recognizing Kb-OVA257_264 complexes 
even though there are at least five peptide sequences within 
OVA that contain recognized Kb-binding motifs. In a study 
of mice immunized with  OVA  sequestered  in  immuno- 
stimulatory complexes (ISCOM) preparations, some uncloned 
CTLs  recognized OVA176-1s3  but  it  was  unclear whether 
these CTLs recognized the OVA-transfected EG7 cells. This 
is the only study of which we are aware that identifies a K b- 
restricted  OVA determinant other than OVA257-264 (59). It 
is notable that the OVA176-183 determinant associates with K  b 
less efficiently than OVA55-62 (33, 59, and data not shown). 
In our experience (Chen, W.,  and J. McCluskey) priming 
mice with the OVA-transfectant EG7, or by osmotic loading 
spleen  cells with  OVA, invariably  leads to  Kb-restricted 
CTLs recognizing only OVA257-264. By contrast,  when mice 
are primed by spleen cell dectroporation using high concen- 
trations (>2 mg/ml) of native OVA, Kb-restricted CTLs of 
mixed specificity can be elicited. Some of these CTLs recog- 
nize the OVAss-62 determinant which we have studied in de- 
tail.  The  equivalent  stoichiometry  of  OVA257-264 and 
OVAss-62 within native OVA allowed us to directly compare 
the presentation of the two determinants after Ag processing. 
Cytoplasmic loading of APCs with native OVA resulted in 
dose-dependent  presentation  of the OVA257-264 at between 
20- and 50-fold greater efficiency than the OVAss-62 deter- 
minant. The dose-dependent increase in expression of the two 
OVA determinants indicates that the Ag processing and pep- 
tide import mechanisms were not limiting for presentation 
of either OVA determinant (Fig. 2, A and B). Moreover, the 
rate of appearance of the two OVA determinants was iden- 
tical in APCs that were electroporated in the presence of OVA, 
washed,  and then fixed at different  time points (data not 
shown), suggesting similar kinetics of TAP-dependent im- 
port into the Elk. Nonetheless it is not possible to formally 
rule out the possibility that differences in the catabolic half- 
life of the two OVA determinants or subtle differences  in TAP 
importation might also contribute to the relative Ag presen- 
tation of OVA2sT-264 and OVA55-62. 
The OVAss-62 determinant is  likely  to  be  the optimal 
length for presentation of this epitope and probably represents 
the naturally presented Ag because peptides that were shorter 
or longer than OVAss-62 were poorly recognized by OVA- 
specific T  hybridomas  and bound very inefficiently to K  b 
molecules on RMA-S cells. However, formal proof that the 
OVAss-62 peptide is naturally presented would require elu- 
tion of this peptide from K  b molecules on APCs, followed 
by sequence or mass  analysis of the peptide  eluate.  The 
OVA2sT-264 peptide eluted from EG7 has been estimated to 
be present at <100 molecules/ceU (48). Therefore, elution of 
the less efficiently presented OVAss-62 peptide is unlikely to 
be feasible with current methodologies. 
The OVA2s7-264 peptide  (50%~-binding •25  nM) was 
*40-fold more efficient at stabilizing K  b on the surface of 
RMA-S cells than the OVAss-62 peptide  (50%m~,-binding 
'~1 #M) at  22-25~  This difference in "affinity" for K  b 
was reflected in part in the greater  instability  of induced 
Kb/OVAss-62  (tl/2  =  2.7  h)  complexes  compared  with 
Kb/OVA2s7-264 (tl/2  =  8.3 h) complexes at 37~  These es- 
timates of Kb-peptide  stability probably reflect relative dis- 
sociation rates and are consistent with the Koa values corre- 
sponding to tl/2  =  3 h found in studies of nonamer peptides 
binding to K a at 37~  (21) but are considerably longer than 
tl/2  values of 2  min for radiolabeled OVA257-264 analogue 
bound to K b (59) and tl/z  =  9.3 rain for iodinated  17 mer 
bound to  D b (22). One of the inherent problems  in es- 
timating relative peptide--MHC  class I affinities using the 
RMA-S Kb-stabilization assay is the inability to distinguish 
direct kinetic differences in offrate and on rate (24). For this 
reason, we studied the kinetic binding of OVA peptide ana- 
logues using biosensor techniques in which octameric OVA 
peptides were altered at position  6 where structural studies 
demonstrate the side chain to be solvent exposed and not 
directly involved in MHC class I-peptide binding.  Relative 
dissociation  rates  of  purified  Kbs  from  OVAzsT-264 and 
OVAss-62 analogues calculated from plasmon resonance studies 
(Kbs/OVAss-62_c6 dissociates about  two  times  faster  than 
bs/OVA257_264_c6) were in agreement with estimates derived 
from RMA-S epitope induction/stabilization  experiments. 
However, the most striking difference in the two OVA pep- 
tides was in their relative kinetic association rates with K b. 
Here the two peptides differed by 10-fold or more at 25~ 
implying a critical role for rapid association of peptides with 
MHC class I molecules to achieve efficient Ag presentation. 
1479  Chen et al. The values of Kon for Kbs/OVA257_264--c6 at 25~  (5.9  x  103 
M -1  s -t)  and  Kbs/OVAss_62-c6  (6.5  x  102  M  -1  S -1)  are 
comparable  to  the  values  of 1,140  M -t  s -1  obtained  for 
binding of radiolabeled nonameric peptides to empty single 
chain K d molecules at 37~  (25) and 720 M-1 s-1 for radio- 
labeled 17 mer bound to D b molecules on EL-4 cells  (22). 
The difference in affinity of K b, and the OVA257-264  (Kd = 
1.56  x  10 -9 M) and OVAss-62 (Kd  =  2.46  x  10 -s M) ana- 
logues was 16-fold as measured by the biosensor assay, how- 
ever the C6-substituted analogue of OVA2sT-~ may slightly 
underestimate the affinity of Kb/OVAzsT-~. Therefore, these 
differences in Kb-peptide affinity are probably sufficient to 
account for most or all of the 20-50-fold differences in pre- 
sentation of the two OVA determinants.  The physiological 
rdevance of kinetic differences in MHC class I-peptide binding 
is likely to vary at different stages of the Ag presentation 
pathway. For example in the ER, where MHC class I-pep- 
tide assembly is thought to take place,  the short half-life  of 
many peptides would require rapid association with class I 
molecules for successful presentation at the cell surface. The 
advantage of a fast on rate would be exaggerated because of 
competition between different peptides and the possible re- 
quirement for displacement of calnexin from newly formed 
class I-calnexin complexes (67, 68).  However, once MHC 
class I-peptide complexes are formed they must remain stable 
long enough for transport  to the cell surface (',,30-45 min 
[69]) and then persist for a time sufficient to allow T  cell 
recognition. Although higher affinity peptides will be favored 
in  Ag presentation,  the  kinetics  of MHC class  I-peptide 
binding need to meet this balance. The results obtained with 
the OVAzsT-~ and OVAss-62 peptides define a threshold  of 
MHC class I-peptide affinity corresponding to an observed 
bias in determinant sdection and relative immunodominance 
of the  OVA257-264 determinant  in  the  anti-OVA  CTL  re- 
sponse in vivo. 
Despite the differences in KS-binding affinity of OVA~7-~s4 
and OVAs~s2 both peptides contain the recognized "binding 
motif' for peptide association with K b (1) and possess con- 
served amino acids between the flanking 5F and 8L anchor 
residues (FEKL versus _FDKL_). Kb-binding of systematically 
substituted analogues of the two peptides indicated that mul- 
tiple  residues  controlled  the  difference in  Kb-binding  be- 
tween the two OVA peptides. For example, substitution of 
P2V -~ I in OVAss~2 improved Kb-binding of this peptide 
fourfold, consistent with the side chain of isoleucine inter- 
acting more efficiently with the Kb-B/D pockets than  the 
shorter side chain of valine (24, 55, 56). Accordingly, some 
perceived "nonanchor" residues may in fact be acting as minor 
anchor sites exerting considerable influence on Ag presenta- 
tion (24).  Some of the OVAss~2 -~ OVA2sT-264 changes in- 
volved residues where the side chains are predicted to be sol- 
vent exposed and not directly involved in binding to K b. For 
example the substitutions of OVAss~2 at P6D -~ E and P4R 
-~  N  both enhanced  stabilization  of K b even though  side 
chains at these positions are thought  to lie outside the K b 
cleft where they are accessible to the TCR. These findings 
support the idea that conformational changes within the pep- 
tide Ag might  exert considerable influence on MHC class 
I-peptide stability.  The summation of enhanced Kb-binding 
of individual  OVAss~2  -~  OVA2s7-~  analogues  shown in 
Table  1 adds up to a  160-fold enhancement  as OVAss-62 is 
substituted  towards  OVAz57-~.  However,  the  observed 
difference between Kb/OVAs~2 and Kb/OVA2sT_~4 binding 
is considerably less than this.  Therefore the data emphasize 
Table  1.  Relative  Ability of OVA  Peptide Analogues  to Stabilize  H-2K  s 
Efficiency of 
Peptide  Amino Acid  peptide-binding  to K  b 
370C (M)  25~  (M) 
OVAss~s2  KVVRFDKL  -  (>10 -s)  1  ('x,10-6) * 
OVAs~2/P1K  ~  S  S .......  +  2 
OVAs~2/P2V  "" I  -  I ......  +  4 
OVAss-62/P3V  -~ I  --  I .....  +  1 
OVAs~2/P4R  ~  N  -  -  -  N  ....  +  2 
OVAs~2/P6D  ~  E  .....  E-  -  +  10 
OVA2s7-~s4  S I INFEKL  1  (exJ2.5  x  10 -6)  1  (r~2.5  x  10 -s) 
OVAasT-~/P1S  "-* K  K .......  0.4  1 
OVA2sT-~4/P2I  ~  V  -V ......  1.2  1.2 
OVA2sT-~/P3I  -~ V  --V .....  0.5  1 
OVAzsT-~s4/P4N -~ R  ---  R ....  0.4  1 
OVAzsT-~4/P6E -* D  .....  D- -  0.4  0.2 
* The concentration of peptide required to give 50%  maximum stabilization of K b on R.MA-S cells has been normalized to a binding efficiency 
of 1.  Values >1 indicate more efficient K b stabilization and values <1 indicate less ef~cient K b binding. The actual 50% maximum peptide concen- 
trations for binding were OVAss-~2 = 10 -6 M, OVA2s~-z64  = 2.5  x  10 -s M at 25 ~ C  and OVAss-~2 >10 -s M, OVAzsr  =  2.5  x  10 -6 M at 37  ~ C. 
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tide binding is not simply additive and instead is dependent 
upon the  sequence context. 
Thus,  the association of peptide Ags with class  I mole- 
cules can be highly sequence dependent despite the presence 
of conserved allele-specific  binding motifs (26, 28, 33, 47). 
This latter finding contrasts with binding studies of poly- 
alanine-substituted peptides showing MHC class I-peptide 
binding energy is controlled almost entirely  by  anchor residues 
and interaction with the peptide backbone (24). It is likely 
that the use of alanine substitutions to study the contribu- 
tions of individual amino adds to peptide-MHC class I binding 
will minimize peptide side chain influences and potentially 
obscure detection of side chain interactions occurring between 
different peptide residues (70). In our studies, the contribu- 
tion of "nonmotif" residues (e.g., P2 and P6) was shown to 
influence the affinity ofpeptide-MHC class I interaction where 
dominant anchor sites were conserved. Most importantly, these 
differences in MHC class I-peptide binding correspond with 
the outcome of the immune response and demonstrate that 
subtle influences at this level can influence physiological Ag 
presentation and the hierarchy of determinant selection in vivo. 
Taken together, these data indicate that immunodominance 
of OVAzsT-z64 and subdominance of the OVAss-62 epitopes 
within OVA are largely accounted for by kinetic differences 
in class I-peptide association resulting  in affinity variation 
and differential Ag presentation.  This difference in Kb-pep  - 
tide association results from the contribution of multiple pep- 
tide side chains rather than altered "dominant anchor" residues 
and suggests considerable complexity in the rules governing 
class  I-peptide  association. 
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